The decision to administer recombinant erythropoietins should be based on a benefit-risk assessment with the participation of the individual patient, which should also take into account the specific clinical context.
Rekombinantsete erütropoetiinide manustamise otsus peab põhinema kasu/ riski vahekorra hindamisel koos patsiendiga, võttes arvesse ka konkreetset kliinilist konteksti.